Jia Jie Biomedical Co., Ltd. (TPEX:4109)
Taiwan · Delayed Price · Currency is TWD 11.35
-0.05 (-0.44%)
Aug 19, 2026, 11:10 AM CST
Jia Jie Biomedical Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 3.09 | 50.26 | 211.37 | 144.15 | -5.47 | 5.34 |
Depreciation & Amortization | 20.08 | 17.53 | 15.8 | 14.89 | 16.87 | 13.44 |
Loss (Gain) From Sale of Assets | 0.06 | -0.01 | 0.58 | 0.12 | -0.48 | 0.53 |
Loss (Gain) From Sale of Investments | -4.75 | -40.24 | -183.75 | -200.25 | - | - |
Loss (Gain) on Equity Investments | - | - | - | -0.31 | - | - |
Provision & Write-off of Bad Debts | -0 | -0.01 | 0.05 | -0.28 | -0.71 | -0.3 |
Other Operating Activities | -2.61 | -0.78 | 10.71 | 1.56 | -1.36 | -0.08 |
Change in Accounts Receivable | -9.45 | -2.7 | -6.72 | -1.57 | -0.08 | -5.79 |
Change in Inventory | -4.37 | -3.18 | 0.41 | 1.96 | -5.84 | -5.75 |
Change in Accounts Payable | 14.18 | 12.01 | -4.87 | 1.09 | -1.37 | 1.39 |
Change in Unearned Revenue | -0.2 | 0.45 | -0.16 | 0.18 | -0.5 | 0.03 |
Change in Other Net Operating Assets | -3 | -11.97 | 0.92 | 33.99 | -9.84 | -4.44 |
Operating Cash Flow | 13.04 | 21.34 | 44.35 | -4.49 | -8.78 | 4.37 |
Operating Cash Flow Growth | 27.51% | -51.87% | - | - | - | -83.86% |
Capital Expenditures | -65.39 | -85.5 | -19.63 | -8.61 | -17.86 | -1.52 |
Sale of Property, Plant & Equipment | 0.06 | 0.08 | 0.09 | 0.05 | 0.55 | 0.89 |
Cash Acquisitions | - | - | -41.3 | - | - | -7.52 |
Investment in Securities | -53.91 | -98.51 | -68.07 | 12.97 | -14.95 | -158.42 |
Other Investing Activities | -2.44 | -2.19 | 0.77 | -1.86 | -2.75 | -6.48 |
Investing Cash Flow | -121.67 | -186.12 | -128.15 | 2.55 | -35.02 | -173.05 |
Short-Term Debt Issued | - | 50 | - | 242.45 | - | - |
Total Debt Issued | 140 | 50 | - | 242.45 | - | - |
Short-Term Debt Repaid | - | - | -75 | -5 | - | - |
Long-Term Debt Repaid | - | -2.65 | -2.7 | -2.88 | -3.73 | -2.49 |
Total Debt Repaid | -52.64 | -2.65 | -77.7 | -7.88 | -3.73 | -2.49 |
Net Debt Issued (Repaid) | 87.36 | 47.35 | -77.7 | 234.57 | -3.73 | -2.49 |
Issuance of Common Stock | - | 360 | 130.73 | - | - | - |
Common Dividends Paid | -59.37 | -59.37 | -49.37 | - | - | - |
Other Financing Activities | 0.79 | 0.53 | -162.43 | - | - | 0 |
Financing Cash Flow | 28.78 | 348.51 | -158.77 | 234.57 | -3.73 | -2.49 |
Foreign Exchange Rate Adjustments | 1.59 | -0.21 | 1.09 | -3.74 | 0.78 | -0.73 |
Net Cash Flow | -78.26 | 183.53 | -241.48 | 228.89 | -46.74 | -171.89 |
Free Cash Flow | -52.35 | -64.15 | 24.72 | -13.1 | -26.64 | 2.85 |
Free Cash Flow Growth | - | - | - | - | - | -88.79% |
Free Cash Flow Margin | -10.17% | -13.22% | 4.60% | -3.94% | -8.38% | 1.18% |
Free Cash Flow Per Share | -0.44 | -0.55 | 0.25 | -0.15 | -0.30 | 0.03 |
Levered Free Cash Flow | -87.97 | -71.31 | 0.17 | 2.6 | -27.76 | -4.52 |
Unlevered Free Cash Flow | -87.3 | -71.14 | 0.57 | 2.82 | -27.69 | -4.49 |
Cash Interest Paid | 1.06 | 0.28 | 0.64 | 0.35 | 0.11 | 0.06 |
Cash Income Tax Paid | 8.25 | 10.38 | 3.41 | 0.84 | 2.11 | -0 |
Change in Working Capital | -2.83 | -5.41 | -10.42 | 35.64 | -17.63 | -14.56 |